TORONTO, July 12, 2018 /CNW/ - GeneNews Limited
("GeneNews" or the "Company") (TSX:GEN) today announced the appointment of David Byram as the
Chief Commercial Officer for its U.S. Lab, Innovative Diagnostic Laboratory, LLP ("IDL"). Mr. Byram will oversee all IDL's
customer-facing activities including sales, client relations and commercial operations.
Mr. Byram is a senior commercial executive with over 25 years of pharmaceutical, biotechnology and medical device industry
leadership experience. He has built successful product launches across multiple therapeutic areas that incorporate innovative
sales and marketing strategies which have driven wide market adoption and revenue generation. Mr. Byram has broad health category
experience including oncology/hematology, gastroenterology, rheumatology, neurology, cardiology and urology. During his
career, Mr. Byram has overseen all commercial operations including sales and marketing, market access and pricing, channel
strategy and new product development. Prior to joining IDL, Mr. Byram was the Vice President, Commercial & Government
Affairs for Braeburn Pharmaceuticals. Prior to Braeburn, he held positions as SVP, Commercial Affairs for Orexo AB/US, US
Director, Public Sector for Indivior plc, and Sr. Director, Strategic Accounts and Public Affairs for Janssen Biotech, a division
of Johnson & Johnson. David is highly focused on delivering healthcare outcomes which create value for patients, physicians,
payers and investors.
"We are extremely pleased to have David join IDL's senior leadership team," commented James R Howard-Tripp, Chairman and CEO
of GeneNews. "With a very experienced executive to energetically manage the company's commercial operations and sales strategy,
we can increase the pace of meeting our targeted sales objectives for 2018."
"It is an exciting time to be in the liquid biopsy space and I look forward to utilizing my commercialization expertise as
well as prior sales experience in oncology and gastroenterology to support IDL's efforts to achieve our growth objectives and
ensure the highest satisfaction of our clients," said Mr. Byram.
About GeneNews
GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized
medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is
to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with
personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of
disease.
Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab
specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer
risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung,
prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information
on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will", "may" and similar
expressions, which reflect the Company's current expectations regarding future events, including with respect to the receipt of
shareholder approval. The forward-looking statements involve risks and uncertainties that could cause actual events to
differ materially from those projected herein including the state of the equity capital markets, the receipt of required
approvals, the future financial and operating performance of the Company and its subsidiaries, requirements for and availability
of additional capital and the general business and political environment including in the healthcare sector. Investors should
consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating
to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company
disclaims any obligation to update these forward-looking statements, except as required by law.
View original content:http://www.prnewswire.com/news-releases/genenews-innovative-diagnostic-laboratory-appoints-david-byram-chief-commercial-officer-300679811.html
SOURCE GeneNews Limited
View original content: http://www.newswire.ca/en/releases/archive/July2018/12/c3272.html